Basilea’s Toctino Receives Marketing Authorisation In Canada

Basilea’s Toctino (alitretinoin), a once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to topical corticosteroids, has obtained regulatory approval from Health Canada.

Toctino has recently been launched in France and is already being marketed in Denmark, Germany and the UK for the treatment of adults with severe chronic hand eczema unresponsive to potent topical corticosteroids.

Toctino has also received marketing authorisation in Austria, Belgium, Finland, Luxemburg, the Netherlands, Spain and Switzerland. Further, Toctino has been recommended for approval in Italy. Alitretinoin is under regulatory review in 15 additional European countries.

Anthony Man, CEO of Basilea, said: “We are delighted that Health Canada has approved the use of Toctino for patients with severe chronic hand eczema unresponsive to potent topical steroids. These patients have often suffered with this chronic debilitating condition for many years. Our rigorous, well designed clinical studies have clearly shown that Toctino has the potential to benefit a significant number of patients suffering from chronic hand eczema.”